A U.S. drug-approval story spread across the group, but the other two names need separate explanations.
[Sep 28, 2026, around 5 p.m. KST; Npay Securities KRX all-market view]
HLB Pharmaceutical KRW 9,620 +30.00% | C-Site KRW 12,870 +30.00%
HLB Pep KRW 5,590 +30.00% | HLB Biostep KRW 3,250 +30.00%
HLB Innovation KRW 19,680 +29.99% | Korea BNC KRW 3,425 +29.98%
HLB Life Science KRW 3,405 +29.96% | HLB KRW 39,700 +29.95%
HLB Panagene KRW 1,432 +29.95% | HLB Therapeutics KRW 2,580 +29.84%
HLB Genex KRW 2,320 +29.83% | HLB Global KRW 2,055 +29.82%
These are values observed on the listing at that time, not a prediction or a guarantee of final pricing.
[Separate the catalysts]
Ten HLB-linked names: Yonhap reported U.S. FDA approval of the bile-duct-cancer treatment Rifixu. It is a direct news backdrop for the group move, not proof that every affiliate's earnings changed equally.
C-Site: a September 23 controlling-stake transfer agreement is a possible relevant disclosure. A single definitive cause of today's move is not established.
Korea BNC: a report described mouse-test results for an obesity-drug candidate. The article appeared after the stock had already reached its upper limit, so it cannot be asserted as the initiating cause.
The image reconstructs the twelve prices and gains from the observed listing. Do not treat a shared rally as a shared fundamental outlook. Not investment advice.
Sources: https://stock.naver.com/market/stock/kr/stocklist/upper ; https://www.yna.co.kr/amp/view/AKR20260928033300008 ; https://v.daum.net/v/20260928113404119 ; https://www.newspim.com/news/view/20260928000713